- Canada to further cut international student, foreign worker permits
- YouTube launches new TV-focused tools for creators
- White Sox heading for worst season in MLB history
- China the top challenge in US history: senior diplomat
- Hong Kong democracy tycoon's son warns time running out
- New migraine drugs no better than cheap painkillers: big study
- Sean 'Diddy' Combs again denied bail in sex trafficking case
- Brewers clinch division title as MLB playoff race heats up
- Man City blunted by 'giant' Inter in Champions League stalemate
- US stocks dip despite larger Fed interest rate cut
- Man City held by Inter as PSG pinch win in Champions League
- All Blacks recall Beauden Barrett for Australia Test
- Fears of all-out war as new Lebanon device blasts kill 20, wound 450
- Spurs late show saves Postecoglou blushes at Coventry
- PSG snatch late goal to beat Champions League debutants Girona
- Gittens' late double gives Dortmund Champions League win at Brugge
- Man City blunted by Inter in Champions League stalemate
- Hidden talent: French Olympic star Marchand opts for disguise
- MrBeast named in California lawsuit over 'Beast Games' show
- Gauff splits with Gilbert as coach after 14-month run
- Hundreds of thousands at risk in Sudan's El-Fasher: UN
- Harvey Weinstein pleads not guilty to new sex crime charge
- Venezuelan opposition candidate says letter conceding election was coerced
- Ukraine official claims Russian advance in Kursk has been 'stopped'
- X update allows app to bypass Brazil ban: internet providers
- Fears of all-out war as new Lebanon device blasts kill 14, wound 450
- US Fed makes aggressive rate cut, weeks before election
- Arsenal's Odegaard faces lengthy injury absence
- India coal expansion risks massive methane growth: report
- China the top challenge in US history, top diplomat says
- US Fed makes larger half-point cut in first reduction since 2020
- Ronaldo's Al Nassr appoint former AC Milan boss Pioli
- Ainslie 'relieved' as British book place in Louis Vuitton Cup final
- Struggling Roma replace sacked icon De Rossi with Ivan Juric
- Women's NBA will add 15th team in Portland in 2026
- Brazil fires need harsher punishment: environmental police boss
- Boeing to start large temporary furloughs amid Seattle strike
- Fears of all-out war as new Lebanon device blasts kill nine, wound 300
- 'Emergency' declared over falling UK butterfly numbers
- McIlroy outlines threats to golf peace deal
- Stock markets, dollar slip before US rate decision
- Russian advance in Kursk 'stopped': Ukraine official to AFP
- UN members demand end to 'unlawful' Israeli occupation of Palestinian territories
- Snapchat pushes 'safer' platform image, but not everyone agrees
- Three dead, 100 wounded in new wave of Lebanon device explosions
- So where does the oceans' plastic waste come from?
- Allied war heroes buried in Netherlands... 80 years on
- Marsh coy over Australia's choice to open alongside Head
- New London sculpture pays tribute to trans community
- Lebanon doctors tell of horror after pager blasts
RBGPF | 5.79% | 60.5 | $ | |
GSK | -0.31% | 42.43 | $ | |
CMSC | 0.02% | 25.055 | $ | |
VOD | 0.49% | 10.23 | $ | |
NGG | -0.46% | 70.05 | $ | |
SCS | 0.71% | 14.11 | $ | |
BTI | -0.34% | 37.88 | $ | |
AZN | 0.06% | 78.58 | $ | |
RYCEF | 1.37% | 6.55 | $ | |
RIO | -0.02% | 62.91 | $ | |
RELX | -0.82% | 47.37 | $ | |
BCC | 1.33% | 137.06 | $ | |
BCE | 3.09% | 35.61 | $ | |
JRI | 0.45% | 13.44 | $ | |
BP | -0.37% | 32.43 | $ | |
CMSD | -0.12% | 24.98 | $ |
Tests of HIV vaccine using mRNA technology have begun
Testing in humans of an HIV vaccine that uses messenger RNA technology has begun, the biotech firm Moderna and the International AIDS Vaccine Initiative said Thursday.
This Phase 1 trial is being carried out in the United States among 56 healthy adults who are HIV negative.
Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS, which kills hundreds of thousands of people around the world each year.
But hopes have been stirred with the success of mRNA technology, which allowed for the development of Covid-19 vaccines in record time, including one from Moderna.
The goal of the vaccine now being tested is to stimulate production of a kind of antibody called "broadly neutralizing antibodies," or bnAbs, which can act against the many variants of HIV that are circulating today.
The vaccine is supposed to teach B lymphocytes, which are part of the immune system, to generate these antibodies.
In this trial, participants are injected with an immunogen -- a substance that can trigger an immune response -- and then a booster immunogen later.
These substances will be delivered with mRNA technology.
"The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process," Moderna and the IAVI, a research organization, said in a statement.
"Further immunogens will be needed to guide the immune system on this path, but this prime-boost combination could be the first key element of an eventual HIV immunization regimen," said David Diemert, a lead investigator at one of the four sites where the trial is being carried out, George Washington University in the US capital.
The immunogens used in this trial were developed by IAVI and the Scripps Research Institute, with support from the Bill & Melinda Gates Foundation, the US National Institute of Allergy and Infectious Diseases and Moderna.
A first trial last year tested the first immunogen but without employing mRNA technology. It showed that the desired immune response was triggered in dozens of people taking part in the research.
The next step was to bring in Moderna with its new mRNA technique.
"Given the speed with which mRNA vaccines can be produced, this platform offers a more nimble and responsive approach to vaccine design and testing," the Moderna-IAVI statement said.
"The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine," said Mark Feinberg, the CEO of IAVI.
K.Brown--BTB